Soleno Therapeutics plunges after short report from Scorpion Capital

[Sorting Medications]
microgen/iStock via Getty Images

Soleno Therapeutics (SLNO) dropped 16% in premarket trading after a new short report from Scorpion Capital.

Scorpion Capital disclosed that it's short Soleno Therapeutics (NASDAQ:SLNO [https://seekingalpha.com/symbol/SLNO]).

Soleno (NASDAQ:SLNO [https://seekingalpha.com/symbol/SLNO]) didn't immediately return Seeking Alpha's email request for comment. 

Soleno has short interest of 11%. [https://seekingalpha.com/symbol/SLNO]

MORE ON SOLENO THERAPEUTICS

* Soleno Therapeutics, Inc. (SLNO) Q2 2025 Earnings Call Transcript [https://seekingalpha.com/article/4810073-soleno-therapeutics-inc-slno-q2-2025-earnings-call-transcript]
* Soleno Therapeutics: Fairly Valued Despite M&A Expectations [https://seekingalpha.com/article/4801523-soleno-therapeutics-fairly-valued-despite-m-and-a-expectations]
* Soleno Therapeutics: Overbought On VYKAT Approval Enthusiasm [https://seekingalpha.com/article/4796360-soleno-therapeutics-overbought-on-vykat-approval-enthusiasm]
* Soleno signals $500M cash war chest and robust Vykat XR launch trajectory while advancing EU expansion [https://seekingalpha.com/news/4480995-soleno-signals-500m-cash-war-chest-and-robust-vykat-xr-launch-trajectory-while-advancing-eu]
* Soleno Therapeutics prices $200M public offering [https://seekingalpha.com/news/4466500-soleno-therapeutics-prices-200m-public-offering]